相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy
Matthew D. Hellmann et al.
CLINICAL CANCER RESEARCH (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2020)
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
Christine Alewine et al.
CLINICAL CANCER RESEARCH (2020)
Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine
Xui-Fen Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
Sarah Talamantes et al.
CANCER MEDICINE (2020)
Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
Emma Gransmark et al.
FRONTIERS IN ONCOLOGY (2020)
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
Andrea B. Apolo et al.
LANCET ONCOLOGY (2020)
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin
Raffit Hassan et al.
CANCER (2020)
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models
Qun Jiang et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer
Adam Cerise et al.
CLINICAL COLORECTAL CANCER (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Robert J. Kreitman et al.
LEUKEMIA (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity
Junxia Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
Yasmin Leshem et al.
TOXINS (2018)
HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy
Diana P. Saraiva et al.
FRONTIERS IN IMMUNOLOGY (2018)
Mesothelin-targeted immunotoxin RG7787 has synergistic antitumor activity when combined with taxanes
Emily Kolyvas et al.
ONCOTARGET (2017)
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity
Yasmin Leshem et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Clinical significance of Tim3-positive T cell subsets in patients with multiple sclerosis
Xuemei Feng et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2016)
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy
Frieder Bauss et al.
MOLECULAR ONCOLOGY (2016)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Kevin Hollevoet et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Christine Alewine et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Raffit Hassan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma
H. Miles Prince et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
William D. Hastings et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights
D Agnello et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2003)
Interferon γ stabilizes the T helper cell type 1 phenotype
YK Zhang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
The effect of Pseudomonas exotoxin A on cytokine production in whole blood exposed to Pseudomonas aeruginosa
MJ Schultz et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2000)